Clinical Trials Logo

Keratoconjunctivitis clinical trials

View clinical trials related to Keratoconjunctivitis.

Filter by:

NCT ID: NCT01179412 Completed - Clinical trials for Viral Conjunctivitis

Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine

Start date: July 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the outcomes of treating epidemic keratoconjunctivitis with 2% povidone-iodine.

NCT ID: NCT01156025 Completed - Clinical trials for Acute Adenoviral Keratoconjunctivitis

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis

Start date: March 2009
Phase: Phase 2
Study type: Interventional

The study objective is to evaluate the efficacy and the safety of GV 550 in comparison to placebo in patients with acute adenoviral keratoconjuncivitis.

NCT ID: NCT01102257 Completed - Dry Eye Syndromes Clinical Trials

Dry Eye Assessment and Management: Feasibility Study

DREAM
Start date: January 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to test a protocol investigating the efficacy of omega-3 fatty acids in treating dry eye disease. The study is termed "feasibility" because its purpose is to demonstrate an ability to execute the proposed protocol with compliance at two sites rather than generate statistically relevant data concerning the safety and efficacy of the supplement in patients with dry eye disease.

NCT ID: NCT01068054 Completed - Clinical trials for Keratoconjunctivitis, Vernal

Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivits (VKC)

Start date: June 2003
Phase: Phase 2/Phase 3
Study type: Interventional

The study was a double-blind, parallel study to compare efficacy of 0.1% tacrolimus ophthalmic ointment vs 2% cyclosporine eye drops in children with vernal keratoconjunctivitis. The duration of the blinded period was 8 weeks followed with 4 weeks of open-period of tacrolimus ointment. The hypothesis was that tacrolimus was as effective as cyclosporine for the treatment of this condition.

NCT ID: NCT01057147 Completed - Dry Eye Clinical Trials

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

Start date: February 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of 2% rebamipide compared to placebo in clearing of fluorescein staining of the central cornea in subjects with dry eye disease.

NCT ID: NCT01027013 Completed - Dry Eye Syndromes Clinical Trials

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

Start date: December 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of rebamipide 2% suspension for the treatment of patients with dry-eye.

NCT ID: NCT00987727 Completed - Dry Eye Syndromes Clinical Trials

Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye

Start date: November 2009
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.

NCT ID: NCT00987467 Completed - Clinical trials for Atopic Keratoconjunctivitis

Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis

Start date: August 2007
Phase: N/A
Study type: Interventional

Atopic keratoconjunctivitis (AKC) is a rare type of ocular allergy that is often associated with eczema. Over time, the complications from this disease process lead to loss of vision due to continual scarring of the corneal surface. The pathophysiology of AKC has not been fully elucidated, and the triggers are still unknown. Corticosteroids are very effective in controlling the acute symptoms of AKC. However, two thirds of patients managed with a combination of oral antihistamine, topical mast cell stabilizer, and intermittent topical steroid regimen eventually developed significant keratopathy and vision loss. Additionally, there are many side effects of corticosteroids, including local immunosuppression, cataract formation, and increased risk of glaucoma. Cyclosporin A is an immunomodulator that specifically inhibits T lymphocytes by blocking the expression of the interleukin-2 receptor. It also blocks the release of inflammatory mediators from mast cells and eosinophils. Cyclosporin has no known side effects except for burning upon instillation, and safe to use over long-term . The investigators have demonstrated that a 0.05% ophthalmic emulsion of cyclosporine has been shown to be effective at improving the ocular signs and symptoms of AKC over short-term. However, the long-term efficacy of cyclosporine A in slowing the natural history of AKC and possible steroid sparing effects have not been assessed. The investigators hypothesize that cyclosporine A can be used as a mainstay treatment of AKC to control signs and symptoms over a long period of time and also prevent the progression of this disease.

NCT ID: NCT00883649 Completed - Clinical trials for Keratoconjunctivitis Sicca

Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye

Start date: September 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effectiveness of a nutritional supplement in post-menopausal women age 40 or older with moderate to severe dry eyes. This study is being conducted to determine if signs and symptoms of dry eye will improve with the use of this nutritional supplement.

NCT ID: NCT00851734 Completed - Clinical trials for Keratoconjunctivitis Sicca

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

Start date: February 2009
Phase: Phase 1
Study type: Interventional

This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.